X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs IPCA LABS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA IPCA LABS TORRENT PHARMA/
IPCA LABS
 
P/E (TTM) x 36.2 40.2 90.2% View Chart
P/BV x 5.6 3.8 148.1% View Chart
Dividend Yield % 1.0 0.1 715.5%  

Financials

 TORRENT PHARMA   IPCA LABS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
IPCA LABS
Mar-17
TORRENT PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,768643 274.9%   
Low Rs1,186503 235.8%   
Sales per share (Unadj.) Rs346.1254.4 136.0%  
Earnings per share (Unadj.) Rs55.216.1 343.3%  
Cash flow per share (Unadj.) Rs73.329.8 246.2%  
Dividends per share (Unadj.) Rs14.001.00 1,400.0%  
Dividend yield (eoy) %0.90.2 543.1%  
Book value per share (Unadj.) Rs257.1194.6 132.1%  
Shares outstanding (eoy) m169.22126.20 134.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.32.3 189.5%   
Avg P/E ratio x26.835.7 75.1%  
P/CF ratio (eoy) x20.119.2 104.7%  
Price / Book Value ratio x5.72.9 195.1%  
Dividend payout %25.46.2 407.8%   
Avg Mkt Cap Rs m249,88772,300 345.6%   
No. of employees `00011.813.3 88.6%   
Total wages/salary Rs m9,9346,960 142.7%   
Avg. sales/employee Rs Th4,971.52,413.5 206.0%   
Avg. wages/employee Rs Th843.2523.2 161.2%   
Avg. net profit/employee Rs Th792.4152.4 519.8%   
INCOME DATA
Net Sales Rs m58,56932,106 182.4%  
Other income Rs m2,233226 989.4%   
Total revenues Rs m60,80232,332 188.1%   
Gross profit Rs m13,7734,448 309.7%  
Depreciation Rs m3,0691,730 177.5%   
Interest Rs m2,056241 853.7%   
Profit before tax Rs m10,8812,703 402.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545675 228.8%   
Profit after tax Rs m9,3362,028 460.3%  
Gross profit margin %23.513.9 169.7%  
Effective tax rate %14.225.0 56.9%   
Net profit margin %15.96.3 252.4%  
BALANCE SHEET DATA
Current assets Rs m53,84117,340 310.5%   
Current liabilities Rs m31,6129,559 330.7%   
Net working cap to sales %38.024.2 156.6%  
Current ratio x1.71.8 93.9%  
Inventory Days Days97100 96.9%  
Debtors Days Days8457 147.3%  
Net fixed assets Rs m42,07920,779 202.5%   
Share capital Rs m846252 335.3%   
"Free" reserves Rs m42,65524,499 174.1%   
Net worth Rs m43,50124,553 177.2%   
Long term debt Rs m22,4083,517 637.1%   
Total assets Rs m101,25039,595 255.7%  
Interest coverage x6.312.2 51.5%   
Debt to equity ratio x0.50.1 359.6%  
Sales to assets ratio x0.60.8 71.3%   
Return on assets %11.35.7 196.3%  
Return on equity %21.58.3 259.8%  
Return on capital %19.610.5 187.1%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m20,06615,617 128.5%   
Fx outflow Rs m5,3045,828 91.0%   
Net fx Rs m14,7629,790 150.8%   
CASH FLOW
From Operations Rs m10,1272,764 366.4%  
From Investments Rs m-7,869-1,432 549.6%  
From Financial Activity Rs m-1,918-1,591 120.5%  
Net Cashflow Rs m212-259 -81.7%  

Share Holding

Indian Promoters % 71.5 45.9 155.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 11.4 61.6%  
FIIs % 12.6 25.3 49.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 17.4 50.6%  
Shareholders   26,511 36,892 71.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 200 Points; Energy Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in green.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jul 17, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - GLENMARK PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS